Beam Therapeutics is a biotechnology company developing precision genetic medicines using a proprietary base editing platform. The company's technology enables single-base modifications in the genome without creating double-stranded DNA breaks, utilizing CRISPR-associated proteins and base editing enzymes. Its portfolio includes risto-cel (formerly BEAM-101), an autologous hematopoietic stem cell therapy for sickle cell disease, and liver-targeting lipid nanoparticle formulations for genetic diseases. Key programs include BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-304 for phenylketonuria, and BEAM-301 for glycogen storage disease type 1a. Beam also develops the ESCAPE platform for non-genotoxic treatment strategies and targeted lipid nanoparticles for in vivo delivery to hematopoietic stem cells. The company serves patients with serious genetic conditions, focusing on hematology and genetic disease indications.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage beamtx.com
Sector Healthcare IR page investors.beamtx.com
Tags
base editing, gene editing, sickle cell disease, alpha-1 antitrypsin deficiency, phenylketonuria, glycogen storage disease, lipid nanoparticles, hematopoietic stem cells, crispr, precision medicine, risto-cel, BEAM-101, BEAM-302, BEAM-304, BEAM-301, ESCAPE, BEAM-103, BEACON trial
Press page —

Metrics

Valuation  
Market cap $ 2.481B
Market cap (USD) $ 2.481B
P/E -28.55
PEG —
P/BV 2.60
P/S 16.92
P/OCF -6.38
P/FCF -6.23
Dividend yield —
Turnover / mcap —
Returns  
ROE -8.1%
ROI -7.4%
ROIC -26.6%
Profit margin -57.2%
Growth  
Revenue growing No
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 10.5%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 76
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 139.743M 63.518M 377.709M 60.92M 51.844M 24K 18K
Net profit -79.992M -376.742M -132.527M -289.088M -370.638M -194.592M -78.326M
Free cash flow -360.048M -356.192M -182.927M -26.424M -113.079M -112.098M -84.521M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 27.72 24.8 27.22 39.11 79.69 81.64 —
Price performance 12m 0.12 -0.09 -0.3 -0.51 -0.02 — —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 31.2M 108M 148M 182M 173M 161M 154M
Cash and deposits (USD) 148M 37.2M 162M 560M 233M 436M 282M 295M
Right-of-use assets (USD) — 19M 86.9M 103M 119M 113M 105M 101M
Cash flow detail
Operating cash flow (USD) — -72M -95.7M -66.3M 22.5M -149M -347M -345M
Purchases of property, plant and equipment (USD) — -12.5M -16.4M -46.8M -49M -33.7M -8.95M -14.9M
Change in payables (cash effect) (USD) — 4.09M 60,000 818,000 2.37M -7.58M 1.81M 6.04M
Interest paid (cash effect) (USD) — -187,000 -561,000 -567,000 -376,000 -160,000 -32,000 0.00
Income taxes paid (cash effect) (USD) — -187,000 -561,000 — — — — 0.00
Share-based compensation (USD) — 7.03M 15.4M 43.6M 84.3M 98.6M 121M 94.2M
Free cash flow (OCF - PPE - intangibles) (USD) — -84.5M -112M -113M -26.4M -183M -356M -360M
Income detail
Research and development expense (USD) — 54.6M 103M 387M 312M 437M 368M 410M
↳ 5y CAGR +46.4% +31.8%
Total comprehensive income (USD) — -78.3M -195M -371M -291M -129M -377M -79.6M
Comprehensive income to owners (USD) — -78.3M -195M -371M -291M -129M -377M -79.6M
Reported May 12, 2020 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 28, 2023 Feb 27, 2024 Feb 25, 2025 Feb 24, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026 at 9:00 AM EST

PDF Version

BEACON Trial Results Selected for Official ASH Press Program

Initial Patient-Reported Outcomes Demonstrate Early and Sustained Improvements in Physical Function, Pain, Fatigue, Emotional and Social Well-Being and Symptom Severity

U.S. Biologics License Application (BLA) Submission for Risto-cel Expected as Early as Year-End 2026

CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans. The presentation has also been selected for ASH’s official press program. Risto-cel is an investigational autologous genetically modified cell therapy being evaluated for the treatment of SCD.

“With more patients and longer follow-up, the updated BEACON data continue to demonstrate risto-cel’s differentiated clinical and manufacturing profile and its potential to provide a meaningful treatment option for patients living with sickle cell disease,” said Amy Simon, M.D., chief medical officer of Beam. “At ASH, we look forward to sharing updated findings from a growing population of adolescent and adult patients from the trial, including, initial patient-reported outcomes data demonstrating improvements compared to baseline across measures of physical function, pain, fatigue and overall well-being. These findings reinforce our confidence in risto-cel as we prepare for an anticipated BLA submission as early as year-end 2026 and work toward bringing this potentially transformative treatment to patients.”

Presentation details are as follows:

Title: Efficacy, Safety, and Patient-Reported Outcomes of Risto-cel in Adolescents and Adults with Sickle Cell Disease: Interim Results from the BEACON Study Abstract: 335 Oral Session: 114. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Clinical and Epidemiological - Therapeutics **Presentation Time:**Saturday, December 12, 2026, 5:00–5:15 p.m. CT Presenter: Ashish Gupta, M.D., MPH, University of Minnesota

Additional abstract accepted for publication only:

Title: Fetal Hemoglobin as a Predictor of Clinical Outcomes and Sickling Parameters in Sickle Cell Disease: A Model-Based Meta-Analysis **Format:**Publication-only in the online abstract issue of Blood, ASH’s official journal **Author:**Haydar Frangoul, M.D., Sarah Cannon Research Institute and TriStar Centennial

About ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) Risto-cel is an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). The one-time therapy consists of autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) that have been base-edited in the promoter regions of the HBG1/2 genes and are administered via a hematopoietic stem cell transplant procedure. The risto-cel edit is designed to inhibit the transcriptional repressor BCL11A from binding to the promoter without disrupting BCL11A expression, leading to increased production of non-sickling and anti-sickling fetal hemoglobin (HbF) and thus mimicking the effects of naturally occurring variants seen in hereditary persistence of fetal hemoglobin. HbF is the predominant hemoglobin variant during development and early life. The safety and efficacy of risto-cel are being evaluated in the ongoing BEACON Phase 1/2 study, an open-label, single-arm, multicenter trial in patients with SCD with severe vaso-occlusive crises (VOCs).

About Sickle Cell Disease Sickle cell disease (SCD), a severe inherited blood disease, is caused by a single point mutation, E6V, in the beta globin gene. This mutation causes the mutated form of sickle hemoglobin (HbS) to aggregate into long, rigid molecules that bend red blood cells into a sickle shape under conditions of low oxygen. Sickled cells obstruct blood vessels and die prematurely, ultimately resulting in anemia, severe pain (crises), infections, stroke, organ failure and early death. SCD is the most common inherited blood disorder in the United States (U.S.), affecting an estimated 100,000 individuals within the U.S. and approximately eight million people worldwide.

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our base editing technology and risto-cel; the potential of risto-cel to provide a meaningful treatment option for patients with sickle cell disease; the significance of the updated clinical data from the BEACON Phase 1/2 trial, including patient-reported outcomes data; our expected presentation at the ASH Annual Meeting; our plans to advance risto-cel, including our anticipated BLA submission as early as year-end 2026, and our other programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to submit a BLA for risto-cel on the timing we anticipate; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events that could delay, limit or prevent further clinical development; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

November 3, 2026 at 7:00 AM EST

PDF Version

Updated BEAM-302 Phase 1/2 Clinical Data Presented at ERS Demonstrated Durable Increases in Functional AAT and Reductions in Mutant Z-AAT; Completion of Dosing in the Global Pivotal Cohort Expected in First Half of 2027

U.S. Biologics License Application (BLA) Submission for Risto-cel in Sickle Cell Disease Expected as Early as Year-End 2026

Dosing in Phase 1/2 Trial of BEAM-304 in PKU Anticipated to Initiate in Early 2027

Initial BEAM-301 Phase 1/2 Data Presented at ESGCT Demonstrated Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa; Enrollment in 60 mg Cohort Underway

Ended Third Quarter 2026 with $1.0 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into Mid-2029

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2026 financial results and provided updates across the company’s hematology and genetic disease franchises.

“Our progress this quarter reflects the growing maturity and momentum of Beam’s platform, with predictable clinical translation across four distinct programs and multiple potentially transformative medicines advancing toward patients, bringing our vision for a new era of genetic medicine increasingly within reach,” said John Evans, chief executive officer of Beam Therapeutics. “We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027. Recently, initial BEAM-301 clinical trial data showed exciting early evidence of clinical activity and provided further clinical validation of our in vivo LNP platform. Together with the planned initiation of BEAM-304 dosing in early 2027, these milestones reinforce our confidence in a platform designed to translate predictably, carry knowledge forward from one program to the next, and progressively expand the number of patients who can benefit from base editing.”

Third Quarter****2026 and Recent Progress and Anticipated Milestones

Liver-targeted Genetic Diseases

**BEAM-302:**BEAM-302, Beam’s lead genetic disease program, is an investigational base editing therapy designed to be a differentiated, first-in-class liver-targeting therapy for alpha-1 antitrypsin deficiency (AATD) that directly corrects the root cause of the disease and has the potential to address both liver and lung manifestations.

  • In September, Beam presented updated clinical data from the Phase 1/2 trial of BEAM-302 at the European Respiratory Society (ERS) Congress 2026, reinforcing its potential as a one-time treatment for both the lung and liver manifestations of AATD. With up to 18 months of follow-up, the data demonstrated durable increases in total and functional AAT, decreased circulating neutrophil elastase activity, and reductions in mutant Z-AAT and toxic circulating Z-polymers following a single dose. Evidence of AAT production under normal physiological control further supports BEAM-302’s potential to restore the body’s natural protective response, with a safety profile consistent with lipid nanoparticle (LNP)-based therapies.

  • Enrollment and dosing continue in the global pivotal cohort of the ongoing Phase 1/2 trial, which is designed to support a potential accelerated approval path in the United States. The company expects to complete dosing in the pivotal cohort in the first half of 2027.

**BEAM-304:**BEAM-304 is an investigational base editing program designed to leverage Beam’s proprietary base editing technology and LNP delivery capabilities to directly and durably correct mutations in the phenylalanine hydroxylase (PAH) gene that cause phenylketonuria (PKU). Beam aims to advance BEAM-304 using a platform approach to develop mutation-specific base editors for the majority of patients with PKU.

  • Beam nominated its third base editor within the BEAM-304 program targeting a third undisclosed PKU mutation. Now encompassing three different base editors for distinct mutations, the company believes the BEAM-304 program has the potential to address up to 50% of PKU patients in the U.S., with ongoing research effort to address additional pathogenic mutations.

  • Beam continues clinical start-up activities for the planned Phase 1/2 trial of BEAM-304. The trial will initially evaluate safety, tolerability and reduction of blood phenylalanine (Phe) levels in patients with the R408W mutation, with the goal of establishing clinical proof of concept for base editing in PKU. The trial is designed to subsequently evaluate base editors for additional mutations within a single clinical program. Beam expects to initiate dosing in the Phase 1/2 trial in early 2027.

**BEAM-301:**BEAM-301, an investigational base editing therapy, aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa).

  • In October, Beam presented initial clinical data from the ongoing Phase 1/2 trial of BEAM-301 at the European Society of Gene & Cell Therapy (ESGCT) Congress. Initial BEAM-301 clinical data demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH) across all patients, with two of three patients in the 40 mg cohort achieving the protocol-defined maximum controlled fasting duration of 15 hours, consistent with restored endogenous glucose production, and complete elimination of starch supplementation. BEAM-301 demonstrated an acceptable safety profile across both doses, consistent with the known risks associated with LNP-based therapies​.

  • Based on the safety and clinical findings observed to date, Beam is enrolling patients in a 60 mg cohort of the ongoing open-label Phase 1/2 dose-exploration study and plans to engage with the U.S. FDA regarding a potential path to approval.

Hematology

**Risto-cel:**Ristoglogene autogetemcel (risto-cel, formerly known as BEAM-101) is an investigational autologous cell therapy with a potentially differentiated profile for the treatment of sickle cell disease (SCD).

  • Beam expects to report updated clinical data by year-end 2026 and submit a U.S. biologics license application (BLA) for risto-cel as early as year-end 2026.

Next-generation Programs in Sickle Cell Disease and Hematology:

  • Beam continues to make significant investments in developing targeted LNPs to deliver gene editing to hematopoietic stem cells (HSCs). Targeted LNPs for HSC delivery have been identified and are in advanced lead optimization.

Corporate Updates

  • In September, Beam appointed Eric Foster as chief commercial officer to lead the company’s commercial organization and strategy as its hematology and genetic disease programs advance toward potential launches. Mr. Foster is a seasoned biopharmaceutical executive with more than 25 years of commercial leadership experience, including senior roles at Ardelyx, Horizon Therapeutics, and GSK.

Upcoming Events Beam management will participate in fireside chats at the following upcoming investor events:

  • **Guggenheim 3rdAnnual Healthcare Innovation Conference in Boston:**Tuesday, November 10, 2026, at 9:00 a.m. ET.

  • **UBS Global Biopharma Conference in London:**Tuesday, November 17, 2026, at 2:00 p.m. GMT.

  • **Jefferies Global Healthcare Conference in London:**Wednesday, November 18, 2026, at 1:00 p.m. GMT.

  • **9thAnnual Evercore Healthcare Conference in Miami:**Wednesday, December 2, 2026, at 8:20 a.m. ET.

The live webcasts will be available in the investor section of the company’s website at www.beamtx.com and will be archived for 60 days following each presentation.

Third Quarter 2026 Financial Results

  • Cash Position: Cash, cash equivalents and marketable securities were $1.0 billion as of September 30, 2026, compared to $1.2 billion as of December 31, 2025.

  • Research & Development (R&D) Expenses: R&D expenses were $110.1 million for the third quarter of 2026, compared to $109.8 million for the third quarter of 2025.

  • General & Administrative (G&A) Expenses: G&A expenses were $31.5 million for the third quarter of 2026, compared to $26.7 million for the third quarter of 2025.

  • Net Income (Loss): Net loss was $134.4 million, or $1.28 per share, for the third quarter of 2026, compared to net loss of $112.6 million, or $1.10 per share, for the third quarter of 2025.

Cash Runway

Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the company’s facility with Sixth Street, will fund anticipated operating expenses and capital expenditure requirements into mid-2029, assuming satisfaction of the conditions applicable to those additional borrowings. This runway is expected to support the company through the potential launch of risto-cel in SCD, execution of the BEAM-302 pivotal development plan in AATD, and clinical proof of concept for BEAM-304 in PKU.

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, AATD, PKU and GSDIa, and our next-generation programs, including our development of targeted LNPs for hematopoietic stem cell delivery; our plans, and anticipated timing, to advance our programs and present data from ongoing clinical trials; the clinical trial designs and expectations for risto-cel, BEAM-103, BEAM-301, BEAM-302 and BEAM-304, including the anticipated timing of clinical trial initiation and expansion; our planned submission of a BLA for risto-cel; our expectations regarding the potential launch of risto-cel; the potential for an accelerated approval path for BEAM-302; our anticipated regulatory interactions and filings; our expectations regarding the funds that will be available to draw under our credit facility with Sixth Street; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; our intentions regarding management’s participation in future investor events; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate or continue human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates, including the delivery modalities we rely on to administer them, may cause serious adverse events; that we may not achieve the funding milestones under our credit facility with Sixth Street; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

October 27, 2026 at 7:00 AM EDT

PDF Version

In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment

Safety Profile of BEAM-301 Consistent with LNP-Based Therapies

Beam Plans to Engage FDA on Potential Path to Approval; Enrollment in 60 mg Dose Cohort Underway

Company to Host Investor Webcast Today, October 27, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported initial data from the ongoing Phase 1/2 clinical trial evaluating BEAM-301 for the treatment of glycogen storage disease type Ia (GSDIa). The data will be presented during a poster session at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany. BEAM-301 is an investigational liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, one of the most prevalent disease-causing mutations in GSDIa and one that is associated with the most severe form of the disease.

“These findings demonstrate the potential for BEAM-301 to fundamentally change how patients with GSDIa manage their disease,” said Rebecca Riba-Wolman, M.D., director of the glycogen storage disease program and disorders of hypoglycemia at Connecticut Children’s and University of Connecticut School of Medicine, and presenting investigator in the BEAM-301 Phase 1/2 trial. “The ability of two patients to achieve 15 hours of controlled fasting and no longer require starch supplementation following a single treatment represents a significant departure from the intensive daily management typically required for this disease. While these are early results, the improvements in glucose regulation and reductions in starch requirements provide encouraging evidence of BEAM-301’s potential to deliver meaningful and lasting benefits for patients.”

BEAM-301 Phase 1/2 Clinical Trial Data Update BEAM-301 is being evaluated in an open-label Phase 1/2 dose-exploration trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy in patients with GSDIa who are homozygous or compound heterozygous for the R83C variant. As of the August 17, 2026, data cutoff, six patients had received a single intravenous infusion of BEAM-301, including three patients treated with 20 mg and three patients treated with 40 mg. Median follow-up across both cohorts was 7.6 months (range: 1.9–16.6 months).

Key highlights include:

  • **Safety Profile Consistent with LNP-Based Therapies:**BEAM-301 demonstrated an acceptable safety profile consistent with LNP-based therapies, with no dose-limiting toxicities, Grade 4 or 5 treatment-emergent adverse events (TEAEs), or treatment discontinuations due to TEAEs reported. All patients experienced at least one TEAE considered related to BEAM-301. Four of six patients experienced serious TEAEs considered related to BEAM-301, including three Grade 3 infusion-related reactions (IRRs). Premedication with shorter-acting steroids, which are typically used in this patient population, may have contributed to the Grade 3 IRRs observed. The steroid premedication and infusion rate regimens have since been modified. Two other serious TEAEs of diarrhea and rhabdomyolysis occurred in two patients; both have resolved. With the exception of a single Grade 2 elevation in aspartate aminotransferase (AST), all transaminase elevations were Grade 1. All liver enzyme elevations resolved without treatment, and total bilirubin remained within normal limits.

  • **Restoration of Endogenous Glucose Production Following a Single Treatment:**BEAM-301 demonstrated dose-dependent improvements in time to fasting hypoglycemia (TTH), a key measure of glucose regulation in patients with GSDIa. Median TTH increased from 2.9 hours at baseline to 4.3 hours at Day 36 in the 20 mg cohort, and from 2.5 hours at baseline to 15.0 hours at Day 36 in the 40 mg cohort. Two of three patients in the 40 mg cohort achieved the protocol-defined maximum controlled fasting duration of 15 hours, consistent with restored endogenous glucose production. During the 15-hour fasting challenges, blood glucose levels were generally maintained within the euglycemic range. One patient in the 40 mg cohort did not show an increase in TTH at the first post-dose assessment; several factors may have contributed, including elevated body mass index (BMI) and heterozygosity for the R83C mutation.

  • **100% Reduction in Daily Starch Supplementation Observed in Two Patients:**Daily starch intake and daily number of starch doses generally decreased following treatment with BEAM-301 (baseline: 6–7 and 5–6 doses/day in the 20 mg and 40 mg cohorts, respectively), with two of three patients in the 40 mg cohort achieving a 100% reduction in daily starch requirements and no longer requiring starch supplementation at their latest reported assessments.

  • **Improvements in Glucose Control Despite Reduced Starch Intake:**Continuous glucose monitoring demonstrated increased time spent in the euglycemic range and decreased time in the hyperglycemic range following treatment with BEAM-301, despite reductions in daily starch intake. Patients generally did not experience an increase in time spent in hypoglycemia. Triglyceride levels were generally comparable to baseline at the latest evaluable time point.

Based on the safety and clinical findings observed to date, Beam is advancing BEAM-301 into the 60 mg dose-escalation cohort, with enrollment currently underway. Beam also plans to engage with the U.S. Food and Drug Administration (FDA) regarding a potential path to approval.

“The promise of base editing is to deliver transformative outcomes that correct the root cause of disease with a one-time therapy. These initial results show that we are continuing to advance toward that vision, generating important clinical proof of concept for BEAM-301 in GSDIa and once again demonstrating the potential of base editing to fundamentally change the treatment paradigm for patients,” said John Evans, chief executive officer of Beam Therapeutics. “These findings also reinforce the strength of our fully integrated platform, combining our proprietary base editing technology, validated delivery capabilities, and internal manufacturing to enable the predictable development and rapid production of precision genetic medicines. We look forward to building on these encouraging results as we advance BEAM-301 into the next dose cohort, engage with regulators on a potential pathway to approval, and progress our broader pipeline.”

ESGCT Investor Event Information Beam will host a live and webcast investor event today, Tuesday, October 27, at 8:00 a.m. ET to review the data presented at this year’s ESGCT congress. The event will be webcast live and can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.beamtx.com. The archived webcast will be available on the company’s website beginning approximately two hours after the event.

About BEAM-301 BEAM-301 is an investigational liver-targeting lipid-nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, one of the most prevalent disease-causing mutations and one that results in the most severe form of glycogen storage disease type Ia (GSDIa). BEAM-301 is being evaluated in a Phase 1/2, open-label, dose-exploration and dose-expansion clinical trial to investigate its safety, tolerability, pharmacodynamics, pharmacokinetics and efficacy in patients with GSDIa.

About Glycogen Storage Disease Type Ia (GSDIa) GSDIa is an autosomal recessive disorder caused by mutations in the G6PC1 gene that disrupt a key enzyme, glucose-6-phosphatase (G6Pase), critical for maintaining glucose homeostasis. Inhibition of G6Pase activity results in low fasting blood glucose levels that can result in seizures and death. Patients with the G6PC1 R83C mutation typically require frequent cornstarch administration, without which they may enter into hypoglycemic shock within one to three hours. There remains significant unmet need for patients with GSDIa.

About Beam Therapeutics Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.

Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our base editing technology and BEAM-301; the potential of BEAM-301 to restore endogenous glucose production and reduce starch requirements in patients with GSDIa; the significance of the initial clinical data as proof of concept for precision genetic medicines; our expected presentation at the ESGCT conference; our plans to engage with the FDA regarding a potential path to approval for BEAM-301; our plans to advance BEAM-301 and our other programs; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements; and our ability to develop lifelong, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events that could delay, limit or prevent further clinical development; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; our ability to build and scale commercial infrastructure, including a sales and marketing organization, to support potential product launches; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Prompts

Beam Therapeutics Inc. (ticker BEAM), listed in United States.

ETFs Holding Beam Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
ARKG 3.60% 3,173,277 $ 65.528M Nov 18, 2026
ARKK 1.94% 11,889,547 $ 245.519M Nov 18, 2026
MEDX 1.51% 8,388 $ 287.876K Jun 30, 2026
HELX 0.93% 7,577 $ 260.043K Jun 30, 2026
JSML 0.38% 53,881 $ 1.375M Jul 31, 2026
ESSC 0.25% 3,554 $ 90.698K Jul 31, 2026
FSEG 0.22% 372 $ 12.767K Jun 30, 2026
AVSC 0.13% 195,771 $ 4.099M Nov 16, 2026
TMSL 0.13% 101,199 $ 3.473M Jun 30, 2026
RESM 0.10% 109 $ 3,740.88 Jun 30, 2026
DFAS 0.05% 749,477 $ 18.01M Nov 12, 2026
FESM 0.03% 49,205 $ 1.689M Jun 30, 2026
MSSM 0.03% 6,560 $ 193.061K Aug 31, 2026
DXUV 0.02% 51,376 $ 1.235M Nov 12, 2026
DFAC 0.01% 456,063 $ 10.959M Nov 12, 2026
DCOR 0.01% 132,930 $ 3.194M Nov 12, 2026
DFSU 0.01% 5,406 $ 129.906K Nov 12, 2026
DFAU 0.00% 26,662 $ 640.688K Nov 12, 2026
DFUS 0.00% 28,806 $ 692.208K Nov 12, 2026
AVUS 0.00% 17,878 $ 374.365K Nov 16, 2026
NTRL short 0.00% -2,361 $ 0.00 Nov 16, 2026